PD-1 Blockade with a DLL3 TCE Potentiates Efficacy in SCLC
Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new therapeutic strategies to improve patient outcomes. At AACR 2026, WuXi Biology presented a poster exploring the combination of PD-1 blockade with a DLL3-targeted T cell engager (TCE) as a potential approach for enhancing antitumor immune responses in SCLC.
In this study, the authors demonstrated that the combination of Tarlatamab and Pembrolizumab produced robust antitumor efficacy in preclinical humanized SCLC models. Mechanistically, the regimen enhanced antitumor immunity by reshaping the tumor microenvironment toward a more activated and immune-supportive phenotype.
These findings provide additional rationale for advancing DLL3-targeted TCEs in combination with immune checkpoint inhibitors as a potential therapeutic strategy for SCLC.
Combining PD-1 Blockade with DLL3-Targeted T Cell Engager Potentiates Antitumor Efficacy in Small Cell Lung Cancer
Related Content
T-cell engagers (TCEs) are designed to redirect T cells toward tumor cells, offering a highly focused approach to immune-mediated killing....
VIEW RESOURCEBispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...
VIEW RESOURCE